deltatrials
Completed PHASE4 NCT01395329

Nebivolol and the Endothelin (ET)-1 System

Sponsor: Forest Laboratories

Conditions Hypertension Prehypertension
Interventions FBF response to Acetylcholine FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min) FBF response to BQ-123+BQ-788+ACh FBF response to Sodium Nitroprusside Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min) Metoprolol Nebivolol Placebo
Updated 11 times since 2017 Last updated: Dec 5, 2018 Started: May 31, 2011 Primary completion: Nov 30, 2016 Completion: Dec 31, 2016

Listed as NCT01395329, this PHASE4 trial focuses on Hypertension and Prehypertension and remains completed. Sponsored by Forest Laboratories, it has been updated 11 times since 2011, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE4

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE4

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE4

▶ Show 6 earlier versions

  1. Feb 2019 — Jan 2021 [monthly]

    Completed PHASE4

  2. Jan 2019 — Feb 2019 [monthly]

    Completed PHASE4

  3. Jun 2018 — Jan 2019 [monthly]

    Completed PHASE4

  4. May 2017 — Jun 2018 [monthly]

    Completed PHASE4

    Status: Active Not Recruiting → Completed

  5. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE4

  6. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE4

    First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Forest Laboratories
  • University of Colorado, Boulder
Data source: University of Colorado, Boulder

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boulder, United States